Fat Mass and Obesity-associated Protein (FTO)
Fat mass and obesity-associated gene (FTO) is a member of the Fe (II)- and oxoglutarate-dependent AlkB dioxygenase family and is linked to both obesity and intellectual disability. Previous studies revealed FTO plays pivotal roles in adipogenesis and energy homeostasis. FTO-deficient mice display postnatal growth retardation and reduced food intake, with a significant reduction of adipose tissue, whereas the overexpression of FTO caused obesity in mice. In addition, the role of FTO as an RNA demethylase of N6-methyladenosine (m6A) may be related to its important roles in neurogenesis, learning and memory. FTO protein is also found to be highly abundant in brain and is associated with reduced brain volume in adolescents and older people. FTO gene deficiency enhances the retention of fear memory and also impairs dopamine receptor 2- and 3-dependent control of neuronal activity and locomotor behavioral responses.
All Product Categories
-
Fat Mass and Obesity-associated Protein (FTO) Related Products (33)
Related Products (33)
-
Antibodies (1)
- 1
- 2
-
FTO-IN-4
0 ImagesCat. No.: HY-139820CAS No.: 2763577-74-6FTO-IN-4 is a potent and selective inhibitor of fat mass obesity-associated protein (FTO).
-
FTO-IN-17
0 ImagesCat. No.: HY-183325CAS No.: 1434867-98-7FTO-IN-17 is an orally active and brain-penetrant FTO (m6A RNA demethylase) inhibitor with an IC50 of 1.1 μM. FTO-IN-17 stably binds the FTO catalytic pocket. FTO-IN-17 protects against Aβ1-42-induced toxicity while increasing global m6A levels and dampening pro-inflammatory gene (CXCL10, TNF-α) expression. FTO-IN-17 ameliorates anxiety-like behavior and rescues hippocampal-dependent spatial, recognition memory and neuroinflammation in Alzheimer's disease mice models.
-
FTO-IN-13
0 ImagesCat. No.: HY-168483CAS No.: 687600-25-5FTO-IN-13 (compound 8t) is a potent FTO inhibitor. FTO-IN-13 shows antiproliferative activity. FTO-IN-13 induces apoptosis. FTO-IN-13 decreases the protein expression of Bcl-2 and Caspase 3 active. FTO-IN-13 decreases MYC and CEBPA gene expression. FTO-IN-13 shows anticancer activity.
-
FTO-IN-5
0 ImagesCat. No.: HY-139821CAS No.: 2763577-75-7FTO-IN-5 is a potent and selective FTO inhibitor, with an IC50 of 0.087 μM for FTO demethylase activity and a Kd of 28.0 nM for direct binding to FTO. The IC50 of FTO-IN-5 for ALKBH5 is 8.98 μM. FTO-IN-5 can be used in studies related to FTO demethylase activity and cancer.
-
FTO-IN-1
0 ImagesCat. No.: HY-138843CAS No.: 2243944-92-3FTO-IN-1 is a fat mass and obesity-associated enzyme (FTO) inhibitor extracted from patent WO2018157843A1, compound 32, with an IC50 of <1 μM. FTO-IN-1 can be used for the research of cancer.
-
FTO-IN-10
0 ImagesCat. No.: HY-156405FTO-IN-10 (compound 7) is a potent human demethylase FTO (the fat mass and obesity-associated protein) inhibitor with an IC50 of 4.5 μM. FTO-IN-10 enters the FTO’s structural domain II binding pocket through hydrophobic and hydrogen bonding interactions. FTO-IN-10 induces DNA damage and autophagic cell death in A549 cells.
-
FTO-IN-12
0 ImagesCat. No.: HY-W026109CAS No.: 955328-22-0FTO-IN-12 (Compound 2) is an inhibitor of fat mass and obesity-related protein (FTO). Kd and IC50 values are 185 nM and 1.46 μM, respectively. FTO-IN-12 can be used in the study of neurodegenerative diseases.
-
Meclofenamic acid sodium hydrate
0 ImagesSynonyms: Meclofenamate sodium hydrateMeclofenamic acid (Meclofenamate) sodium hydrate is a non-steroidal anti-inflammatory agent. Meclofenamic acid sodium hydrate is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid sodium hydrate competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid sodium hydrate is a non-selective gap-junction blocker. Meclofenamic acid sodium hydrate inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
-
DDO-02267
0 ImagesCat. No.: HY-170668CAS No.: 2919768-58-2DDO-02267 is a selective and lysine-targeting covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. DDO-02267 increases N6-methyladenosine (m6A) levels and targets the ALKBH5-AXL signaling axis. DDO-02267 can serve as a probe for investigating the biological function of mRNA demethylase.
-
Meclofenamic acid (Standard)
0 ImagesCat. No.: HY-117275RCAS No.: 644-62-2Synonyms: Meclofenamate (Standard)Meclofenamic acid (Standard) is the analytical standard of Meclofenamic acid. This product is intended for research and analytical applications. Meclofenamic acid (Meclofenamate) is a non-steroidal anti-inflammatory agent. Meclofenamic acid is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker. Meclofenamic acid inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
-
FTO-IN-15
0 ImagesCat. No.: HY-179266FTO-IN-15 (Compound 8a) is a potent and selective dual-competitive FTO inhibitor with an IC50 of 43.7 nM, showing high selectivity over ALKBH3 and ALKBH5. FTO-IN-15 substantially inhibits FTO demethylation by simultaneously occupying the substrate and 2-oxoglutarate (2-OG) pockets. FTO-IN-15 can be used for the research of acute myeloid leukemia (AML).
-
Meclofenamic acid sodium (Standard)
0 ImagesMeclofenamic acid (sodium) (Standard) is the analytical standard of Meclofenamic acid (sodium). This product is intended for research and analytical applications. Meclofenamic acid (Meclofenamate) sodium is a non-steroidal anti-inflammatory agent (NSAID). Meclofenamic acid sodium is a non-selective gap-junction blocker and a highly selective inhibitor of fat - and obesity-related enzyme (FTO). Meclofenamic acid sodium has anti-inflammatory and antitumor activities.
- 1
- 2
